These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22113445)

  • 1. Serum HER2/ECD value in stage I and II early breast cancer: need of a lower cut-off?
    Badzek S; Kelovic VL; Plestina S; Humar I; Veir Z; Mihaljevic Z
    Wien Klin Wochenschr; 2011 Dec; 123(23-24):726-31. PubMed ID: 22113445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
    Kong Y; Dai S; Xie X; Xiao X; Lv N; Guo J; Li L; Jia W; Zhang Y; Liu W; Wei W; Xie X
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):275-84. PubMed ID: 22116318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.
    Ludovini V; Gori S; Colozza M; Pistola L; Rulli E; Floriani I; Pacifico E; Tofanetti FR; Sidoni A; Basurto C; Rulli A; Crinò L
    Ann Oncol; 2008 May; 19(5):883-90. PubMed ID: 18187484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Kahlert S; Stieber P
    Clin Chim Acta; 2014 Mar; 430():86-91. PubMed ID: 24412321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between serum HER2 ECD, TIMP-1 and clinical outcomes in Taiwanese breast cancer.
    Tsai HP; Chen SC; Chien HT; Jan YY; Chao TC; Chen MF; Hsieh LL
    World J Surg Oncol; 2012 Feb; 10():42. PubMed ID: 22339939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression.
    Reix N; Malina C; Chenard MP; Bellocq JP; Delpous S; Molière S; Sevrin A; Neuberger K; Tomasetto C; Mathelin C
    Breast Cancer Res Treat; 2016 Nov; 160(2):249-259. PubMed ID: 27709352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer.
    Shi HZ; Wang YN; Huang XH; Zhang KC; Xi HQ; Cui JX; Liu GX; Liang WT; Wei B; Chen L
    World J Gastroenterol; 2017 Mar; 23(10):1836-1842. PubMed ID: 28348489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT; Johansson H; Colleoni M; Zorzino L; Passerini R; Orlando L; Viale G
    Anticancer Res; 2004; 24(2C):1261-6. PubMed ID: 15154657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative serum HER2 extracellular domain levels in primary invasive breast cancer.
    Lee SB; Lee JW; Yu JH; Ko BS; Kim HJ; Son BH; Gong G; Lee HJ; Kim SB; Jung KH; Ahn JH; Lee W; Sung J; Ahn SH
    BMC Cancer; 2014 Dec; 14():929. PubMed ID: 25491647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer.
    Ma L; Yang HY; Han XH; Li J; Wang F; Zhang CL; Yao JR; Shi YK
    Chin Med J (Engl); 2012 Nov; 125(22):4104-10. PubMed ID: 23158151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum HER2 extracellular domain levels and HER2 circulating tumor cell status in patients with metastatic breast cancer.
    Aurilio G; Sandri MT; Pruneri G; Zorzino L; Botteri E; Munzone E; Adamoli L; Facchi G; Cullurà D; Verri E; Rocca MC; Zurrida S; Iacovelli R; Nolè F
    Future Oncol; 2016 Sep; 12(17):2001-8. PubMed ID: 27255717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer.
    Garoufali A; Kyriakou F; Kountourakis P; Yioti I; Malliou S; Nikaki A; Kardara E; Frangos I; Koumna S; Baziotis N; Scorilas A; Ardavanis A
    J BUON; 2008; 13(3):409-13. PubMed ID: 18979558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer.
    Bramwell VH; Doig GS; Tuck AB; Wilson SM; Tonkin KS; Tomiak A; Perera F; Vandenberg TA; Chambers AF
    Breast Cancer Res Treat; 2009 Apr; 114(3):503-11. PubMed ID: 18437556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of serum HER2-ECD levels in patients with gastric cancer.
    Oyama K; Fushida S; Tsukada T; Kinoshita J; Watanabe T; Shoji M; Nakanuma S; Okamoto K; Sakai S; Makino I; Nakamura K; Hayashi H; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Kitagawa H; Fujimura T; Tajiri R; Ooi A; Ohta T
    J Gastroenterol; 2015 Jan; 50(1):41-5. PubMed ID: 24557054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.
    Carney WP; Neumann R; Lipton A; Leitzel K; Ali S; Price CP
    Clin Breast Cancer; 2004 Jun; 5(2):105-16. PubMed ID: 15245613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.
    Vazquez-Martin A; Fernandez-Real JM; Oliveras-Ferraros C; Navarrete JM; Martin-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2009 Dec; 35(6):1369-76. PubMed ID: 19885560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The extracellular domain of Her2 in serum as a biomarker of breast cancer.
    Perrier A; Gligorov J; Lefèvre G; Boissan M
    Lab Invest; 2018 Jun; 98(6):696-707. PubMed ID: 29491426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS; Gagnon R; Di Leo A; Press MF; Arbushites M; Koehler M
    J Clin Oncol; 2009 Nov; 27(33):5552-8. PubMed ID: 19858400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
    Domingo-Domenech J; Fernandez PL; Filella X; Martinez-Fernandez A; Molina R; Fernandez E; Alcaraz A; Codony J; Gascon P; Mellado B
    Ann Oncol; 2008 Feb; 19(2):269-75. PubMed ID: 17998285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.